AstraZeneca PLC

AZN

GB0009895292

Pharmaceuticals

Market Closed - London S.E. Other stock markets 11:35:23 2024-05-03 am EDT			5-day change	1st Jan Change
12,050 ^GBX	-0.87%		+0.52%	+13.68%

May. 03	Angle shares up on assay development deal with AstraZeneca	AN
May. 03	Angle shares up on assay development deal with AstraZenaca	AN

ASTRAZENECA : Buy rating from Berenberg

January 15, 2021 at 03:48 am EST

Berenberg analyst Luisa Hector maintains his Buy rating on the stock. The target price is lowered from GBX 10500 to GBX 10000.

Latest news about AstraZeneca PLC

Angle shares up on assay development deal with AstraZeneca	May. 03	AN
Angle shares up on assay development deal with AstraZenaca	May. 03	AN
Angle Plc to Supply Prostate Cancer Androgen Receptor Detection Assay to AstraZeneca	May. 03	MT
AIM WINNERS & LOSERS: Fletcher King optimistic; Angle in Astra deal	May. 03	AN
Confident start before US jobs data	May. 03	AN
InterContinental Hotels makes first-quarter progress	May. 03	AN
AstraZeneca Says Calquence Combination Improves Progression-Free Survival in Phase 3 Mantle Cell Lymphoma Trial	May. 02	MT
AstraZeneca: research into respiratory diseases	May. 02	CF
AstraZeneca Announces Positive High-Level Results from an Interim Analysis of the Echo Phase III Trial	May. 02	CI
AstraZeneca PLC Announces Positive High-Level Results from an Interim Analysis of the Echo Phase III Trial	May. 02	CI
AstraZeneca: encouraging results in lymphoma	May. 02	CF
AstraZeneca notes positive trial results for Calquence treatment	May. 02	AN
AstraZeneca's Blood Cancer Combo Extends Progression-free Survival in Late-stage Study	May. 02	MT
Ipsen: new President for North America	May. 02	CF
AstraZeneca PLC Announces Calquence combination improved PFS in 1L MCL	May. 02	CI
FTC Challenging 'Junk' Patent Listings for Ozempic, Victoza, Other Medications	Apr. 30	MT
Top Midday Stories: Shares of Eli Lilly, HSBC Get Post-Earnings Bump; BBVA Exploring Merger With Sabadell; FTC Disputes 300 'Junk' Patent Listings	Apr. 30	MT
FTC Challenging 'Junk' Patent Listings for Ozempic, Victoza, Other Medications	Apr. 30	MT
FTC Challenging 'Junk' Patent Listings for Ozempic, Victoza, Other Medications	Apr. 30	MT
FTC Challenging 'Junk' Patent Listings for Ozempic, Victoza, Other Medications	Apr. 30	MT
ASTRAZENECA : Deutsche Bank gives a Neutral rating	Apr. 30	ZD
J&J, Bristol Myers lose challenges to US drug price negotiation program	Apr. 29	RE
European Equities Close Mixed in Monday Trading; Economic Sentiment Falls in April; Lawsuit Dents Deutsche Bank Shares	Apr. 29	MT
AIM ImmunoTech Says Safety Evaluation of First Dose Level of Pancreatic Cancer Study Completed	Apr. 29	MT
AstraZeneca Says Enhertu Phase 3 Trial Shows 'Statistically Significant' Progression-Free Breast Cancer Survival Improvement	Apr. 29	MT

AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows: - product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases); - collaboration revenue (4.4%). Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).

Sector

Pharmaceuticals

Calendar

2024-05-19 - American Thoracic Society International Conference - Abstarct Number - P297

Related indices

STOXX EUROPE 600 (EUR) , FTSE 100

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

ASTRAZENECA : Strong Q1 raises hopes of a guidance upgrade

April 25, 2024 at 12:02 pm EDT

More Strategies

Ratings for AstraZeneca PLC

Trading Rating

Investor Rating

ESG Refinitiv

B+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

151.2 USD

Average target price

164.5 USD

Spread / Average Target

+8.76%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ASTRAZENECA PLC	+13.68%	234B
NOVO NORDISK A/S	+21.85%	546B
JOHNSON & JOHNSON	-4.77%	359B
MERCK & CO., INC.	+16.97%	323B
ABBVIE INC.	+5.69%	290B
NOVARTIS AG	+3.65%	198B
ROCHE HOLDING AG	-11.12%	194B
AMGEN INC.	+8.08%	167B
PFIZER, INC.	-3.40%	157B
SANOFI	+1.72%	123B

Other Pharmaceuticals

AstraZeneca PLC

Equities

AZN

GB0009895292

Pharmaceuticals

ASTRAZENECA : Buy rating from Berenberg

Latest news about AstraZeneca PLC

Chart AstraZeneca PLC

Company Profile

Income Statement Evolution

Analysis / Opinion

Ratings for AstraZeneca PLC

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Pharmaceuticals